Reimbursed Care Access in Bhutan

Currently classified under Bhutan’s schedules that mirror the 1971 UN psychotropics list and treated as a controlled psychotropic substance with no authorized routine medical use outside of approved research. Bhutan’s Narcotic Drugs and Psychotropic Substances framework incorporates the UN schedules (which list psilocybin/psilocin) and makes such substances subject to the controlled‑drug rules administered by the national authorities. # #

Currently classified as a strictly controlled psychotropic substance under the national schedules (aligning with the 1971 Convention) and there is no authorized medical/insured access outside of approved clinical research. Use, possession, importation or distribution outside lawful medical or research channels is prohibited and subject to enforcement. # #

Esketamine (the pharmaceutical Spravato product) is not listed as an approved, reimbursed psychiatric product in Bhutan’s publicly available controlled‑drug and medicines framework; there is no established national reimbursement pathway or authorized outpatient certified REMS‑style program in Bhutan for esketamine, and it is not used as a reimbursed psychiatric therapy in routine care. Ketamine itself is managed under Bhutan’s controlled‑drug system for legitimate medical uses (see Ketamine entry), but esketamine as a branded psychiatric nasal product is not registered for routine clinical use or reimbursement in Bhutan to date, and would require BFDA registration and specific programmatic approval before any public or private insurer reimbursement could be considered. # #

Ketamine is available and controlled for legitimate medical uses (notably anesthesia) under Bhutan’s classification system that makes certain controlled narcotics and psychotropic substances available for medical use within government hospital settings and regulated supply chains. The national medicines framework distinguishes controlled substances that may be supplied only in government hospital settings under Schedule C1/C2 provisions, and the Bhutan Food & Drug Authority’s Controlled Substances & Medical Device Division oversees these controls. In practice this means ketamine is used as an anesthetic within regulated hospital settings and is subject to strict storage, prescription and dispensing rules; there is no evidence of an established, reimbursed program for ketamine’s psychiatric (off‑label) use for depression in Bhutan’s public insurance, and private access would be limited to the institutional medical setting that holds and dispenses controlled anesthetics. Seizure reports also document ketamine as a substance appearing in enforcement activity, reflecting regulatory control of supply and diversion risks. # # #

Currently classified under Bhutan’s schedules as a psychotropic substance listed in the UN 1971 schedules (DMT is enumerated in the Schedule I listing incorporated by Bhutanese law) and has no authorized medical use outside approved clinical research. Possession, distribution or import without explicit authorization for research or medical/scientific purposes is prohibited. # #

Currently classified as a strictly controlled substance under Bhutan’s adoption of UN psychotropic schedules (5‑MeO‑DMT is regarded within the class of controlled tryptamines and there is no authorized medical use in Bhutan outside approved research). Authorized access would be limited to formally approved scientific studies; otherwise it remains prohibited. # #

Currently classified as a strictly controlled substance under national drug scheduling laws with no authorized medical use outside of approved clinical research. Bhutan’s schedules mirror the UN psychotropic lists and prohibit unauthorized medical use of substances such as ibogaine; any clinical research program would require specific authorization from national authorities. # #

Currently classified as a strictly controlled substance scenario under Bhutanese law when it contains internationally scheduled psychotropic compounds (e.g., DMT) and has no authorized medical use outside approved research; ceremonial or informal use would fall afoul of national controlled‑substance provisions unless a formal research exemption or specific authorization is obtained. # #

Mescaline is explicitly listed in the Schedule I entries incorporated into Bhutan’s domestic schedules (aligned with the 1971 Convention) and is treated as a controlled psychotropic substance with no routine medical or reimbursed use outside approved scientific research. Possession, manufacture or distribution outside authorized channels is prohibited. # #

Phenethylamine/‘2C‑’ family compounds are controlled in many jurisdictions and the Bhutan regulatory framework treats novel psychoactive phenethylamines as controlled psychotropic substances; there is no authorized medical use or reimbursement, and access is limited to sanctioned research only. Enforcement activity and the authority to amend schedules are managed through the national narcotics control mechanisms. # #